Li, Tommy

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Hutchings, M., Mous, R., Clausen, M. R., Johnson, P., Linton, K. M., Chamuleau, M. E. D., Lewis, D. J., Sureda Balari, A., Cunningham, D., Oliveri, R. S., et al. (2021) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 337

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Lala, M., Li, T. R., de Alwis, D. P., Sinha, V., Mayawala, K., Yamamoto, N., Siu, L. L., Chartash, E., Aboshady, H., & Jain, L. (2020) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersPharmaceutical studies and practices

Cited by 165

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas

Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., Elliott, B., DeMarco, D., Salcedo, T., Egerod, F. L., Sasser, K., Ahmadi, T., et al. (2022) · Clinical Pharmacology & Therapeutics

Monoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and Treatment

Cited by 34

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Vose, J. M., Feldman, T., Chamuleau, M. E. D., Kim, W. S., Lugtenburg, P., Kim, T. M., Costa, P. A., Cheah, C. Y., Glimelius, I. C., Hess, B., et al. (2023) · Blood

Lymphoma Diagnosis and TreatmentCAR-T cell therapy research

Cited by 14

Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma.

Li, T., Gibiansky, L., Parikh, A., Putnins, M., Chiu, C. W., Sacchi, M., Feng, H., Ahmadi, T., Gupta, M., & Xu, S. (2025) · Clinical Pharmacology & Therapeutics

Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

Cited by 7

Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma

Dandamudi, D. B., Konieczna, I. M., Calabrese, K. M., Wielgos-Bonvallet, M., Kweekel, C., Gresnigt-van den Heuvel, E., Iyer, R., Ellis, P., Rodriguez, L., Parikh, A., et al. (2025) · Leukemia & Lymphoma

Lymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

Cited by 5

Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., DeMarco, D., Salcedo, T. W., Lihme Egerod, F., & Gupta, M. (2020) · Blood

Monoclonal and Polyclonal Antibodies ResearchStatistical Methods in Clinical Trials

Cited by 4